The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatic Complications from Immune Checkpoint Inhibitors

Rheumatic Complications from Immune Checkpoint Inhibitors

December 16, 2021 • By Nilasha Ghosh, MD, MS, & Anne R. Bass, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
3D rendering of immune checkpoint molecules on a T cell and a dendritic cell.

3D rendering of immune checkpoint molecules on a T cell and a dendritic cell.

Alpha Tauri 3D Graphics / shutterstock.com

You Might Also Like
  • Reassuring Data on Immune Checkpoint Inhibitors in Autoimmune Disease
  • Checkpoint Inhibitors May Be Retried after Immune Adverse Event, with Close Monitoring
  • Study Assesses Immune Checkpoint Inhibitors Safety in Rheumatic Disease
Explore This Issue
December 2021

Immune checkpoint inhibitors (ICIs), such as anti-programmed cell-death 1/programmed death-ligand 1 (anti-PD-1/PD-L1) or anti-CTL-associated protein (anti-CTLA-4), have dramatically changed the treatment of advanced cancers over the past decade. ICIs block T cell inhibition, thus increasing the anti-tumor immune response. ICIs are used not only for metastatic cancer, but also as adjuvant treatment for some stage 3 cancers, and they are most effective for tumors with a high mutational burden.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

However, these agents often cause immune-related adverse events (irAEs). Of all such adverse events, 6–7% are rheumatic in nature.1 Given the growing use of ICIs, particularly for common malignancies, such as non-small cell lung cancer, most rheumatologists will evaluate and manage such patients in routine clinical practice. This field is in its infancy, so the evidence guiding treatment decisions is sparse. What follows are some typical case scenarios and our answers to questions that often arise.

Case 1

A 71-year-old man with metastatic non-small cell lung cancer treated with three months’ of nivolumab (an anti-PD-1) develops joint pain, swelling and stiffness, most severe in the right knee. Knee arthrocentesis is consistent with an inflammatory arthritis. After one month of relief from an intra-articular steroid injection, he presents to you with bilateral, symmetrical arthritis in his metacarpophalangeal and proximal interphalangeal joints, wrists, shoulders and knees. How should you treat him?

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

ICI-arthritis

This patient has developed an inflammatory arthritis, ICI-arthritis, precipitated by anti-PD-1 treatment. ICI-arthritis occurs in 4% of patients treated with an ICI.2 The median time to onset is four months; however, it can occur days after the first infusion of ICI or even months after ICI treatment has been discontinued.3

Patients with ICI-arthritis may present with mono- or oligoarthritis, often involving the knees; a rheumatoid arthritis-like, poly­articular pattern that may overlap with polymyalgia rheumatica; or more rarely, a spondyloarthritis pattern (see Table 1,4).

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Over time, a lower extremity oligoarthritis may evolve to a symmetrical, polyarticular pattern. Less common presentations, including a tenosynovitis-only pattern and osteo­arthritis exacerbations, have been described.

Evaluation of these patients should include bloodwork, arthrocentesis, if possible, and imaging. Other causes of inflammatory arthritis, such as infection, crystal disease or reactive arthritis, should be ruled out. Rheumatoid factor and anti-cyclic citrullinated peptide antibody are positive in about 10% of patients, but it is unknown whether this reflects post-ICI treatment seroconversion or persistence of pre-treatment seropositivity.3

Although ICI-arthritis is often too acute for erosive disease to be noted on X-ray imaging, erosions have been demonstrated by ultrasound in some patients, and proliferative pannus formation and bone erosions can also be seen pathologically (see Figures 1A–C, opposite).5 Review of patients’ surveillance positron emission tomography (PET) scans can help identify bone metastases, if they are present, and magnetic resonance imaging (MRI) can also be used for patients with atypical presentations.

irAEs are assigned a grade as determined by the Common Terminology for Cancer Adverse Effects (CTCAE) criteria.6 Grades 1 and 2 are defined as mild and moderate pain, respectively, and inflammation that does not interfere with activities of daily living (ADLs); to achieve grade 3, severe pain must interfere with ADLs.

ICI-myositis tends to occur within two months of ICI initiation, although it can occur later as well. As with other irAEs, the most severe cases most frequently occur soon after treatment with the ICI begins.

CTCAE grading does a poor job of distinguishing the severity of arthritis activity. Thus, clinicians may find it useful to monitor response to therapy using rheumatoid arthritis disease activity measures, such as the Clinical Disease Activity Index (CDAI), the Disease Activity Score for 28 Joints (DAS28) and the Routine Assessment of Patient Index Data 3 (RAPID3).

Treatment Approaches

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions Tagged With: immune checkpoint inhibitor (ICI), immune-related adverse eventsIssue: December 2021

You Might Also Like:
  • Reassuring Data on Immune Checkpoint Inhibitors in Autoimmune Disease
  • Checkpoint Inhibitors May Be Retried after Immune Adverse Event, with Close Monitoring
  • Study Assesses Immune Checkpoint Inhibitors Safety in Rheumatic Disease
  • Check It Out: Understanding Immune-Related Adverse Events from Immune Checkpoint Inhibitors

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.